WO2007111282A1 - グリコヘモグロビン濃度測定方法および濃度測定装置 - Google Patents
グリコヘモグロビン濃度測定方法および濃度測定装置 Download PDFInfo
- Publication number
- WO2007111282A1 WO2007111282A1 PCT/JP2007/056110 JP2007056110W WO2007111282A1 WO 2007111282 A1 WO2007111282 A1 WO 2007111282A1 JP 2007056110 W JP2007056110 W JP 2007056110W WO 2007111282 A1 WO2007111282 A1 WO 2007111282A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- concentration
- light
- glycated hemoglobin
- wavelength
- measuring
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/74—Optical detectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/86—Signal analysis
- G01N30/8675—Evaluation, i.e. decoding of the signal into analytical information
- G01N30/8679—Target compound analysis, i.e. whereby a limited number of peaks is analysed
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8822—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving blood
Definitions
- the present invention relates to a technique for measuring the concentration of glycohemoglobin contained in a sample such as blood.
- HPLC device high performance liquid chromatography device
- HPLC high performance liquid chromatography
- the general HPLC apparatus 9 prepares a sample containing a biological component in the sample preparation unit 90 and then introduces the sample into the analytical column 91, and the biological component is analyzed in the analytical column 91. It is configured to be adsorbed on the filler.
- a biological sample in which the hemolyzed blood is diluted is introduced into the analytical column 91 after hemolyzing red blood cells collected from the whole blood.
- the biological component adsorbed on the filler is eluted by supplying the eluent to the eluent bottle 93 force analysis column 91 by the liquid feed pump 92.
- the eluent containing the biological component from the analytical column 91 is introduced into the photometric mechanism 94, and the biological component is analyzed by continuously measuring the absorbance of the eluent containing the biological component in the photometric mechanism 94. .
- the photometric mechanism 94 irradiates the light from the light source 97 while the eluent containing biological components flows through the flow path 96 of the photometric cell 95, and the transmitted light at that time. Is received by the light receiving unit 98.
- the wavelength of light received by the light receiving unit 98 is selected by the interference filter 99, while the light receiving unit 98 outputs a signal having an output level corresponding to the amount of received light. Since the photometric measurement of the eluent in the photometric mechanism 94 is performed continuously, the relationship between the elution time and the amount of received light (absorbance) can be obtained as a chromatogram as shown in FIG.
- the HPLC apparatus 9 further calculates the concentration based on the chromatogram, which is the change in absorbance over time.
- concentration of glycohemoglobin is calculated as the proportion of glycohemoglobin in the total amount of hemoglobin (the part indicated by cross-hatching in Fig. 15).
- the amount of oxygen and other gases dissolved in the eluent varies depending on the temperature of the eluent. Therefore, when the temperature outside the apparatus (environment temperature) fluctuates, or when the environment temperature is different. When biological components are analyzed, the dissolved gas state (dissolution amount) in the eluent is different. For this reason, when the dissolved oxygen concentration in the eluent fluctuates with changes in ambient temperature, the ratio of oxyhemoglobin to deoxyhemoglobin in hemoglobin varies. Further, in the biological sample introduced into the analytical column 91, the ratio of oxyhemoglobin to deoxyhemoglobin in hemoglobin may vary with each measurement.
- the photometric mechanism 94 has a maximum absorption of oxyhemoglobin.
- the wavelength of 415 nm is used as the measurement wavelength. For this reason, the ratio of oxyhemoglobin and deoxyhemoglobin is different in environments where the environmental temperature varies greatly, making accurate measurement difficult when measuring them at the same wavelength. It becomes.
- Patent Document 1 Japanese Patent Application Laid-Open No. 7-120447
- the present invention has an object to make it possible to appropriately measure the concentration of projectohemoglobin even when the ratio between oxyhemoglobin and deoxyhemoglobin is different. Means for Solving the Problems
- the glycated hemoglobin concentration measuring method provided in the first aspect of the present invention is a method for measuring the glycated hemoglobin concentration based on the light that progresses in the sample force when the sample is irradiated with light. And measuring the concentration of glycohemoglobin based on light having a plurality of measurement wavelengths having peak wavelengths in a wavelength range of 400 to 450 nm.
- the glycated hemoglobin concentration is measured.
- the present invention can be applied to a method for measuring the concentration of glycated hemoglobin using liquid chromatography.
- the glycated hemoglobin concentration is calculated based on, for example, a three-dimensional chromatogram with the measurement wavelength, elution time, and detection amount as variables. More specifically, for example, the glycated hemoglobin concentration is calculated as a volume corresponding to the total amount of hemoglobin in the three-dimensional chromatogram or a ratio occupied by a volume corresponding to glycated hemoglobin or an integrated value in the integrated value.
- Glycohemoglobin concentration may be calculated by calculating the ratio of darcohemoglobin with the elution time and detection amount at each measurement wavelength as variables and averaging the ratio of darcohemoglobin at each measurement wavelength. .
- Glycohemoglobin concentration is calculated as the ratio of the area corresponding to glycohemoglobin in the area corresponding to the total amount of hemoglobin in the two-dimensional chromatogram of the peak value of the detected amount of hemoglobin at each measurement wavelength and the elution time.
- Glycohemoglobin concentration peaks in the first light quantity, which is the amount of light having a peak wavelength in the wavelength range of 400 to 420 nm where the sample force also advances, and in the wavelength range of 420 to 440 nm where the sample force advances. It can also be measured based on the second light amount, which is the amount of light having a wavelength.
- the glycated hemoglobin concentration calculates the oxyhemoglobin concentration or a value that correlates with this concentration based on the first light amount, while the glycated hemoglobin concentration correlates with the concentration based on the second light amount.
- the sum of the oxyhemoglobin concentration and the deoxyhemoglobin concentration, or the value correlated with the oxyhemoglobin concentration and the value correlated with the deoxyhemoglobin concentration. can do.
- the glycohemoglobin concentration method of the present invention utilizes liquid chromatography
- the relationship between the elution time obtained based on the first light amount and the detected amount is shown.
- Chromatogram of the first chromatogram corresponding to oxyhemoglobin and the second chromatogram corresponding to deoxyhemoglobin showing the relationship between the dissolution time obtained based on the second light intensity and the detected amount. Based on the above, the concentration of disruptohemoglobin may be calculated.
- the sample is obtained, for example, by hemolyzing blood cells.
- a glycated hemoglobin concentration measuring device including a photometric mechanism that irradiates a sample with light from a light source and receives light that also advances the sample force at that time in a light receiving unit.
- the photometric mechanism is configured so that light having a plurality of wavelengths having a peak wavelength in a wavelength range of 400 to 450 nm can be distinguished and received by the light receiving unit, and the glycohemoglobin is characterized in that A concentration measuring device is provided.
- the light receiving unit is configured to be capable of continuously or intermittently receiving light having different peak wavelengths in a wavelength range of at least 415 to 430 nm.
- the present invention can be applied to a glycohemoglobin concentration measuring apparatus using liquid chromatography.
- the glycated hemoglobin concentration measuring apparatus further includes a calculation unit configured to calculate the glycated hemoglobin concentration based on a three-dimensional chromatogram using the wavelength, elution time, and detection amount as variables. Is done.
- the calculation unit is configured to calculate the glycated hemoglobin concentration, for example, as a volume corresponding to the total amount of hemoglobin in the three-dimensional chromatogram or a ratio occupied by a volume corresponding to the glycated hemoglobin or an accumulated value in the accumulated value. ing. More specifically, for example, in the two-dimensional chromatogram in which the elution time obtained based on the above-described three-dimensional chromatogram and the peak value of the detected amount are variables, the calculation unit can calculate the area corresponding to the total amount of hemoglobin. It is configured to calculate the glycated hemoglobin concentration as a percentage of the area corresponding to glycated hemoglobin.
- the calculation unit also calculates chromatogram power with the elution time and detection amount at each peak wavelength as variables, calculates the ratio of darcohemoglobin, and averages the ratio of darcohemoglobin at each peak wavelength to determine the concentration of glycohemoglobin.
- the area corresponding to glycohemoglobin occupies the area corresponding to the total amount of hemoglobin. Calculate as a percentage It can be configured as follows.
- the glycated hemoglobin concentration measuring device of the present invention includes a first light amount that is an amount of light having a peak wavelength in a wavelength range of 400 to 420 nm that proceeds from a sample force, and a light beam that travels from a sample. Based on the second light amount that is the amount of light having a peak wavelength in the wavelength range of 440 nm, a calculation unit that calculates the glycohemoglobin concentration may be provided. For example, the calculation unit calculates the oxyhemoglobin concentration or a value related to this concentration based on the first light amount, while the deoxyhemoglobin concentration or a value correlated to the concentration based on the second light amount. And the sum of the oxyhemoglobin concentration and the deoxyhemoglobin concentration, or the sum of the value correlated with the oxyhemoglobin concentration and the value correlated with the deoxyhemoglobin concentration. Configured to calculate concentration.
- the calculation unit corresponds to oxyhemoglobin indicating the relationship between the elution time obtained based on the first light quantity and the detected amount. Based on the chromatogram obtained by superimposing the first chromatogram and the second chromatogram corresponding to deoxyhemoglobin indicating the relationship between the elution time and the detection amount obtained based on the second light intensity V. It may be configured to calculate the projectohemoglobin concentration.
- the sample is obtained, for example, by hemolyzing blood cells.
- FIG. 1 is a schematic configuration diagram showing an HPLC apparatus which is an example of a glycated hemoglobin measuring apparatus according to a first embodiment of the present invention.
- FIG. 2 is a cross-sectional view for explaining a photometric mechanism in the HPLC apparatus shown in FIG.
- FIG. 3 is a block diagram showing the main part of the HPLC apparatus shown in FIG. 1.
- FIG. 4 is a flowchart for explaining the operation of the HPLC apparatus shown in FIG.
- FIG. 5 is a flowchart for explaining the concentration measurement process in the arithmetic circuit in the HPLC apparatus shown in FIG. 1.
- FIG. 6 is an example of a three-dimensional chromatogram obtained in the arithmetic circuit.
- FIG. 7 illustrates the concentration measurement process in the arithmetic circuit according to the second embodiment of the present invention. It is a flowchart for this.
- FIG. 8A is a graph showing the relationship between the measurement wavelength and absorbance at a specific time
- FIG. 8B is a two-dimensional chromatogram created based on the maximum absorbance at the specific time.
- FIG. 9 is a flowchart for explaining concentration measurement processing in an arithmetic circuit according to a third embodiment of the present invention.
- FIG. 11 is a graph showing the relationship between environmental temperature and glycated hemoglobin concentration in Example 1
- FIG. 12 is a graph showing the relationship between environmental temperature and glycated hemoglobin concentration in Comparative Example 1
- FIG. 13 is a schematic configuration diagram showing an HPLC apparatus which is an example of a conventional glycohemoglobin measuring apparatus.
- FIG. 14 is a cross-sectional view for explaining a photometric mechanism in the HPLC apparatus shown in FIG.
- FIG. 15 is an example of a chromatogram obtained from the HPLC apparatus shown in FIG. Explanation of symbols
- the HPLC apparatus X shown in FIG. 1 corresponds to an example of the glycated hemoglobin concentration measuring apparatus of the present invention, and is configured to measure glycated hemoglobin concentration using whole blood. It is a thing.
- the HPLC apparatus X includes a plurality of eluent bottles 10, 11, 12 (three in the drawing), a degassing device 2, a sample preparation unit 3, an analysis unit 4, a photometric mechanism 5, and an arithmetic circuit 6.
- Each of the eluent bottles 10, 11, 12 holds an eluent to be supplied to an analysis column 40 described later.
- eluents for example, kaffers with different pH and salt concentrations are used.
- the degassing device 2 is for removing dissolved gas from the eluent before supplying the eluent to the analysis unit 4 (analytical column 40), and is connected via pipes 70A, 70B, and 70C.
- the eluent bottles 10, 11, 12 are connected to the Mayunoredo 41 of the analysis unit 4 via self-tubes 71A, 71B, 71C.
- the sample preparation unit 3 is for preparing a sample to be introduced into the analysis column 40 from blood cell components collected from the blood collection tube 13.
- the sample preparation unit 3 has a sampling nozzle 30, a preparation liquid tank 31, and a dilution tank 32.
- the sampling nozzle 30 is for collecting various liquids including the blood sample 14 in the blood collection tube 13.
- the sampling nozzle 30 is capable of sucking and discharging the liquid and moving in the vertical and horizontal directions. It is possible.
- the operation of the sampling nozzle 30 is controlled by a control means (not shown).
- the preparation liquid tank 31 holds a preparation liquid for preparing an introduction sample to be introduced into the analysis column 40 based on the blood sample 14.
- the preparation liquid tank 31 holds, as preparation liquids, hemolyzed blood for lysing red blood cells, diluted liquid for diluting the hemolyzed blood, and the like.
- the dilution tank 32 is for providing a place for lysing red blood cells in the blood sample 14 and preparing a sample for introduction by diluting the hemolyzed blood.
- This dilution tank 32 is connected to an injection valve 43 in an analysis unit 4 to be described later via a pipe 72.
- the sample force for introduction prepared in the dilution tank 32 is connected to the analysis column 40 via the injection valve 43. It is configured to be introduced.
- the analysis unit 4 controls the adsorption and elution of biological components with respect to the packing material of the analytical column 40, and supplies various biological components to the photometric mechanism 5.
- the temperature is controlled by.
- the set temperature in the analysis unit 4 is about 40 ° C, for example.
- the analytical column 40 holds a filler for selectively adsorbing hemoglobin in the sample.
- the filler for example, a methacrylic acid ester copolymer is used.
- the analysis unit 4 has a mold 41, a liquid feed pump 42, and an injection valve 43.
- the marhold 41 selectively supplies the eluent from the specific eluent bottles 10 0, 11, 12 of the plurality of eluent bottles 10, 11, 12 to the injection valve 43. It is intended.
- the hold 41 is connected to the deaerator 2 through pipes 71A, 71B, 71C, and is connected to the injection valve 43 through a pipe 73.
- the liquid feed pump 42 is for applying power for moving the eluent to the analysis column 40 via the injection valve 43, and is provided in the middle of the pipe 73.
- the liquid feed pump 42 is operated, for example, so that the flow rate of the eluent is 1.0 to 2 OmlZmin.
- the injection valve 43 collects a fixed amount of the sample for introduction and allows the sample for introduction to be introduced into the analysis column 40.
- the injection valve 43 includes a plurality of introduction ports and discharge ports (not shown). Yes.
- An injection loop 44 is connected to the injection valve 43.
- the injection loop 44 is capable of holding a fixed amount (for example, several / z L) of liquid, and the injection loop 44 communicates with the dilution tank 32 from the dilution tank 32 by appropriately switching the injection valve 43.
- an injection valve 43 for example, a hexagonal noble can be used.
- the photometric mechanism 5 is for optically detecting hemoglobin contained in the eluent from the analytical column 40, and includes a photometric cell 50, a light source 51, and a beam splitter. 5 2. It has a light receiving system 53 for measurement and a light receiving system 54 for reference.
- the photometric cell 50 is for defining a photometric area. This photometric cell 50 has an introduction channel 50A, a photometry channel 50B, and a discharge channel 50C, and these channels 50A, 50B, and 50C communicate with each other.
- the introduction channel 50A is used to introduce the eluent from the analysis column 40 (see FIG. 1) into the photometric channel 50B, and is connected to the analysis column 40 via a pipe 75.
- the photometric flow path 50B circulates the eluent to be measured and provides a field for photometric measurement of the eluent, and is formed in a straight line.
- the photometric flow path 50B is open at both ends, and both ends are closed by the transparent cover 55.
- the discharge channel 50C is for discharging the eluent from the photometric channel 50B, and is connected to the waste liquid tank 15 via a pipe 76 (see FIG. 1).
- the light source 51 is for irradiating light to the eluent flowing through the photometric channel 50B.
- the light source 51 is arranged in a state of facing the end face 50Ba (transparent cover 55) of the photometric flow path 50B so that the optical axis L passes through the center of the photometric flow path 50B.
- the light source 51 may have a wavelength range that can be emitted in accordance with a concentration calculation method in a calculation unit 61 (see FIG. 3) to be described later. Usually, light having a wavelength range of 400 to 500 nm is used. What can emit light, for example, a neuron lamp is used.
- the light source 51 it is possible to use a light source other than the halogen lamp, for example, one provided with one or a plurality of LED elements.
- the beam splitter 52 divides the light emitted from the light source 51 and transmitted through the photometric flow path 50B and makes it incident on the measurement light receiving system 53 and the reference light receiving system 54. On the optical axis L, it is arranged in a state inclined by 45 degrees.
- the beam splitter 52 various known ones such as a half mirror can be used.
- the measurement light receiving system 53 selectively receives light having a target wavelength out of the light transmitted through the beam splitter 52, and is disposed on the optical axis L.
- the measurement light receiving system 53 includes a wavelength selection unit 53A and a light receiving element 53B for receiving the light transmitted through the wavelength selection unit 53A.
- the wavelength selection unit 53A selects the wavelength of light to be transmitted according to the concentration calculation method in the calculation unit 61 (see FIG. 3) described later.
- known spectroscopic means such as an interference filter, a sharp cut filter, and craiding can be employed.
- As the light receiving element 53B a photodiode Can be used.
- the reference light receiving system 54 is for acquiring data for suppressing the influence of the turbidity and scattering of the eluent from the analysis column 40 (see Fig. 1), and is reflected by the beam splitter 52. Of the light whose optical path has been changed, the reference wavelength of 500 nm is selectively received.
- the measurement light receiving system 74 includes an interference filter 54A that selectively transmits 500 nm light, and a light receiving element 54B that receives the light transmitted through the interference filter 54A.
- a photodiode can be used as the light receiving element 54B.
- the arithmetic circuit 6 includes a control unit 60 and a calculation unit 61.
- the control unit 60 is for controlling the operation of each unit. More specifically, the control unit 60 controls the turning on / off of the light source 51, and controls the wavelength selection unit 53A to select the wavelength of light to be received by the light receiving element 53B. , Controls concentration calculation processing in the calculation unit 61.
- the calculation unit 61 is for calculating the glycohemoglobin concentration in whole blood based on the light reception results of the light receiving elements 53B and 54B.
- the calculation unit 61 stores a program necessary for calculation, and its operation is controlled by the control unit 60.
- the eluent is supplied to the analytical column 40 (S2).
- the eluent is supplied from the eluent bottles 10, 11 and 12 to the injection valve 43 through the degassing device 2 and the hold 41 by the power of the liquid feed pump 42.
- the eluent bottle 10, 11, or 12 is supplied by controlling the hold 41.
- the eluent supplied to the injection valve 43 is supplied to the analysis power ram 40 via the pipe 74.
- an introduction sample to be introduced into the analytical column 40 is prepared (S3).
- a blood sample 14 is first collected from the blood collection tube 13. Collection of the blood sample 14 from the blood collection tube 13 is performed by operating the sampling nozzle 30. The blood sample 14 collected by the sampling nozzle 30 It is supplied to the dilution tank 32 by operating the Gnozzle 30. Further, a hemolyzing agent and a diluent are sequentially supplied from the preparation tank 31 to the dilution tank 32, and a sample for introduction is prepared by mixing the liquid in the dilution tank 32 by pipetting operation using the sampling nozzle 30. .
- the sample for introduction is introduced into the analytical column 40 (S4).
- the introduction sample is introduced into the analysis column 40 by switching the injection valve 43 so that the introduction sample of the injection loop 44 is introduced into the analysis column 40 together with the eluent.
- glycohemoglobin is adsorbed to the packing material by introducing the sample for introduction. After glycated hemoglobin is adsorbed on the packing material, the type of eluent supplied to the analytical column 40 is appropriately switched by the hold 41 to elute the glycated hemoglobin adsorbed on the packing material.
- the eluent containing glycohemoglobin discharged from the analysis column 40 is supplied to the photometric cell 50 of the photometric mechanism 5 through the pipe 76 and photometrically measured (S6).
- the eluent is introduced into the photometric cell 50 through the pipe 75 and the introduction flow path 50A, and this eluent passes through the photometry flow path 50B and the discharge flow path 50C and then passes through the pipe 76 to the waste liquid tank. Guided to 15.
- the photometric mechanism 5 when the eluent from the analysis column 40 passes through the photometric channel 50B, the light source 51 continuously irradiates the eluent with light.
- the light transmitted through the photometric flow path 50B is split by the beam splitter 52 and then received by the measurement light receiving system 53 and the reference light receiving system 54.
- the wavelength selector Light of a specific wavelength that has passed through 53A is selectively received by the light receiving element 53B.
- the reference light receiving system 54 In the reference light receiving system 54, light having a reference wavelength of 500 nm transmitted through the interference filter 54A is selectively received by the light receiving element 54B.
- the results of light reception by the light receiving elements 53B and 54B are output to the arithmetic circuit 6, where the concentration of glycohemoglobin is calculated (S7).
- the density calculation processing in the calculation circuit 6 is performed according to the procedure of the flowchart shown in FIG.
- photometry is performed for each wavelength at a specific time (S10). More specifically, while the light is continuously emitted from the light source 51, the wavelength selection unit 53A is controlled by the control unit 60, and the wavelength of the light received by the light receiving element 53B is changed over time in the above wavelength range. To change. That is, the wavelength of light received by the light receiving element 53B is changed continuously or intermittently. It should be noted that photometry with the wavelength changed in the above wavelength range is repeated.
- Fig. 6 shows the force when the wavelength is changed intermittently.
- a two-dimensional chromatogram is obtained for each measurement wavelength.
- the constant wavelength is also variable, a three-dimensional chromatogram with elution time, absorbance, and measurement wavelength as variables can be obtained.
- the measurement wavelength interval is very small (eg, 0.1 to 2 nm), and the wavelength is a variable.
- the plot points are more continuous than discrete.
- the absorbance corresponding to glycated hemoglobin at each wavelength at the same time is integrated (S12).
- the volume of the portion corresponding to glycohemoglobin in the three-dimensional chromatogram in FIG. 6 is calculated as the integrated value of the area of the portion corresponding to hemoglobin in the two-dimensional chromatogram at each measurement wavelength.
- the ratio of glycohemoglobin to the total amount of hemoglobin is calculated (S13). That is, the ratio of the volume (integrated value) corresponding to glycohemoglobin out of the volume (integrated value) corresponding to the total amount of three-dimensional hemoglobin in FIG. 6 is calculated and used as the glycohemoglobin concentration (%).
- the wavelength is changed continuously or intermittently over a wavelength range including 415 nm, which is the maximum absorption wavelength of oxyhemoglobin, and 430 nm, which is the maximum absorption wavelength of doxyhemoglobin.
- the glycated hemoglobin concentration is calculated based on the change in absorbance. That is, in the present invention, the concentration of glycated hemoglobin is calculated by taking into account the influence of deoxyhemoglobin rather than calculating the concentration of glycated hemoglobin by paying attention mainly to oxyhemoglobin.
- the state of dissolved gas in the eluent fluctuates and the ratio of oxyhemoglobin to deoxyhemoglobin in hemoglobin fluctuates, or oxyhemoglobin and deoxy in the introduction sample introduced into the analytical column 40 are changed. Even if the ratio to oxyhemoglobin changes, it will not be affected.
- the concentration when measuring the glycated hemoglobin concentration in an environment where the temperature outside the HPLC apparatus X (environment temperature) varies or in a different environment temperature, or in the sample introduced into the analytical column, Even when the concentration varies, it is possible to measure the stable glycated hemoglobin concentration regardless of the ratio of oxyhemoglobin to deoxyhemoglobin in the eluent.
- the calculation of the glycated hemoglobin concentration is based on, for example, calculating the proportion of glycated hemoglobin in the total amount of hemoglobin based on a two-dimensional chromatogram at each measured wavelength, and also calculating the glycated hemoglobin at each measured wavelength. Calculate the average value of the ratio, and use the average value as the glycated hemoglobin concentration.
- the method of density calculation processing in the calculation circuit 6 is This is different from the previous embodiment.
- photometry is performed at specific times at a plurality of wavelengths selected from a wavelength range of 400 to 450 nm, preferably 415 to 430 nm (S20). This is the same as S10 (see FIG. 5) in the first embodiment.
- S20 a wavelength range of 400 to 450 nm, preferably 415 to 430 nm
- FIG. 8A a graph showing the relationship between the measurement wavelength and the absorbance at each time is obtained.
- the glycated hemoglobin concentration (%) is calculated as the area corresponding to the amount of glycated hemoglobin relative to the area corresponding to the total amount of hemoglobin (S22).
- the measurement wavelength a wavelength range including 415 nm, which is the maximum absorption wavelength of oxyhemoglobin, and 430 nm, which is the maximum absorption wavelength of deoxyhemoglobin, is used.
- the glycated hemoglobin concentration is calculated from the maximum absorbance measured in the range. Therefore, as in the case of the first embodiment of the present invention, it is possible to measure a stable glycated hemoglobin concentration regardless of the ratio of oxyhemoglobin to deoxyhemoglobin in the eluent from the analytical column 40. Become.
- the present embodiment is different from the previous embodiment in the method of concentration calculation processing in the arithmetic circuit 6.
- photometry is performed at specific times at 415 nm and 430 nm (S30). More specifically, while the light is continuously emitted from the light source 51, the control unit 60 controls the wavelength selection unit 53A so that the wavelength of the light received by the light receiving element 53B is between 415 nm and 430 nm. Switch alternately with. Such measurement wavelength switching is repeated. As a result, as shown in FIG. 10, oxyhemoglobin when the measurement wavelength is 415 nm.
- Reference two-dimensional chromatogram (dotted line in Fig. 10) and doxyhemoglobin reference two-dimensional chromatogram (chain line in Fig. 10) when the measurement wavelength is 430 nm. Obtained as the relationship between elution time and absorbance. .
- the glycated hemoglobin concentration is calculated from the oxyhemoglobin-based two-dimensional chromatogram (one-dot chain line in Fig. 10) when the measurement wavelength is 415 nm (S31).
- the concentration calculation result when the measurement wavelength is set to 415 nm and the concentration calculation result when the measurement wavelength is set to 430 nm are added together to obtain the glycohemoglobin concentration (S33).
- the measurement wavelength the measurement result of 415 nm which is the maximum absorption wavelength of oxyhemoglobin, the maximum absorption wavelength of deoxyhemoglobin, and the measurement result of 430 nm are added together to calculate the glycohemoglobin concentration. is doing. Therefore, as in the case of the first embodiment of the present invention, it is possible to measure a stable glycohemoglobin concentration regardless of the ratio of oxyhemoglobin and deoxyhemoglobin in the eluent from the analytical column 40. .
- the glycohemoglobin concentration is calculated based on a chromatogram (solid line in FIG. 10) obtained by adding the chromatogram when the measurement wavelength is 415 nm and the chromatogram when the measurement wavelength is 430 nm. May be.
- the measurement wavelength when obtaining an oxyhemoglobin-based chromatogram is not limited to 415 nm, and a wavelength range of 400 to 420 nm may be selected. Measurement for obtaining a oxyhemoglobin-based chromatogram The wavelength is not limited to 430 nm, and a force ranging from 420 to 440 nm may be selected.
- the present invention is not limited to the embodiment described above, and can be variously modified.
- the force that the amount of hemoglobin was acquired as the absorbance in addition to the case of performing by one light receiving element 53B, a light receiving element corresponding to the number of measurement wavelengths is provided or light receiving is performed. A method using a light emitting element having an area may be used.
- the present invention is not limited to an HPLC apparatus for measuring the concentration of glycated hemoglobin in blood, but is also applicable to a liquid chromatographic apparatus other than the HPLC apparatus or other glycated hemoglobin concentration measuring apparatus when a sample other than blood is used. It can also be applied to.
- the concentration of glycated hemoglobin was measured using the glycated hemoglobin measuring device (ADAMS Ale HA-8160; manufactured by ARKRAY, Inc.) when the ambient temperature was 10 ° C, 20 ° C and 30 ° C.
- Photodiode array (“UV-visible multi-wavelength detector")
- Glycohemoglobin concentration is determined by measuring the total amount of hemoglobin and the amount of glycated hemoglobin for each lnm in the wavelength range of 415 to 430 nm, and then integrating the total amount of glycated hemoglobin in the previous wavelength range. Calculated as a percentage of the value.
- the concentration of glycated hemoglobin was measured under the same conditions as in Example 1 except that the measurement wavelength was fixed, and was calculated as a ratio of the amount of glycated hemoglobin to the total amount of glycated hemoglobin.
- the measurement results of glycated hemoglobin are shown in Table 2 and FIG.
- Example 1 the integrated value when the measurement wavelength is changed between the maximum absorption wavelength (415 nm) of oxyhemoglobin and the maximum absorption wavelength (430 nm) of deoxyhemoglobin.
- the glycated hemoglobin concentration was calculated by the above, as shown in Table 1 and Fig. 11, even if the ambient temperature changed in the range of 10 to 30 ° C, the measured value was not greatly affected by the ambient temperature. It became a substantially constant value.
Landscapes
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Health & Medical Sciences (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Engineering & Computer Science (AREA)
- Library & Information Science (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07739551.5A EP2012111B1 (en) | 2006-03-24 | 2007-03-23 | Method of measuring glycohemoglobin concentration and apparatus for concentration measurement |
CN2007800187887A CN101484792B (zh) | 2006-03-24 | 2007-03-23 | 糖基血红蛋白浓度测定方法和浓度测定装置 |
US12/225,540 US8268625B2 (en) | 2006-03-24 | 2007-03-23 | Method of measuring glycated hemoglobin concentration and concentration measuring apparatus |
JP2008507482A JP5279485B2 (ja) | 2006-03-24 | 2007-03-23 | グリコヘモグロビン濃度測定方法および濃度測定装置 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006082095 | 2006-03-24 | ||
JP2006-082095 | 2006-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007111282A1 true WO2007111282A1 (ja) | 2007-10-04 |
Family
ID=38541199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/056110 WO2007111282A1 (ja) | 2006-03-24 | 2007-03-23 | グリコヘモグロビン濃度測定方法および濃度測定装置 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8268625B2 (ja) |
EP (1) | EP2012111B1 (ja) |
JP (1) | JP5279485B2 (ja) |
CN (1) | CN101484792B (ja) |
WO (1) | WO2007111282A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010181350A (ja) * | 2009-02-09 | 2010-08-19 | Shimadzu Corp | クロマトグラフ用データ処理装置 |
JP2012500401A (ja) * | 2008-08-21 | 2012-01-05 | バイオ−ラッド ラボラトリーズ,インコーポレイティド | 分析物の比を決定する校正表面方法 |
JP2013529780A (ja) * | 2010-06-25 | 2013-07-22 | インペリアル イノベイションズ リミテッド | 小型hplc装置 |
JPWO2016147415A1 (ja) * | 2015-03-19 | 2017-10-19 | 株式会社島津製作所 | クロマトグラフ用制御装置 |
JP2019007865A (ja) * | 2017-06-26 | 2019-01-17 | アークレイ株式会社 | 液体クロマトグラフィ装置 |
US10712320B2 (en) | 2015-10-14 | 2020-07-14 | Alps Alpine Co., Ltd. | Flow channel structure and measuring device for measurement target liquid |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5843509B2 (ja) * | 2010-07-26 | 2016-01-13 | アークレイ株式会社 | クロマトグラムの表示方法 |
CN107402178B (zh) * | 2011-04-15 | 2020-05-05 | 罗氏血液诊断股份有限公司 | 测量细胞体积和成份 |
US9176154B2 (en) * | 2012-12-12 | 2015-11-03 | Bio-Rad Laboratories, Inc. | Calibration process and system |
JP6048373B2 (ja) * | 2013-04-09 | 2016-12-21 | 株式会社島津製作所 | クロマトグラフ用データ処理装置及びデータ処理方法 |
WO2015015555A1 (ja) * | 2013-07-29 | 2015-02-05 | 株式会社島津製作所 | クロマトグラフ用データ処理装置及びデータ処理方法 |
CN105518454B (zh) * | 2013-09-02 | 2018-04-10 | 株式会社岛津制作所 | 色谱仪用数据处理装置以及方法 |
JP6062837B2 (ja) * | 2013-09-30 | 2017-01-18 | 株式会社日立ハイテクノロジーズ | 液体クロマトグラフ用検出器 |
CN104730183B (zh) * | 2014-12-17 | 2016-05-18 | 广州标旗电子科技有限公司 | 液相色谱阵列式紫外可见检测器重叠信号的分离方法 |
CN105115918A (zh) * | 2015-08-12 | 2015-12-02 | 泉州装备制造研究所 | 基于吸收光谱的pH值快速在线检测装置及方法 |
US10527594B2 (en) * | 2016-04-20 | 2020-01-07 | Arkray, Inc. | Liquid chromatography measurement method, liquid chromatography measurement instrument, and liquid chromatography measurement program storage medium |
CN108195839A (zh) * | 2018-01-03 | 2018-06-22 | 常州恒达生物科技有限公司 | 一种图像视频处理系统及设备 |
CN115508568A (zh) * | 2019-01-29 | 2022-12-23 | 美国西门子医学诊断股份有限公司 | 降低血红蛋白A1c测定中的英脱利匹特/脂血干扰的浊度归一化算法和方法 |
CN114200070B (zh) * | 2021-12-14 | 2024-07-16 | 嘉兴市唯真生物科技有限公司 | 一种液相色谱分析装置 |
WO2023223176A1 (en) * | 2022-05-14 | 2023-11-23 | Shanmukha Innovations Private Limited | An apparatus, kit and methods for detecting thalassemia hemoglobin in a sample |
CN117717334B (zh) * | 2024-02-07 | 2024-07-05 | 荣耀终端有限公司 | 数据获取方法及电子设备 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05256851A (ja) * | 1992-03-16 | 1993-10-08 | Hitachi Ltd | 糖化ヘモグロビンの測定方法及び装置 |
JPH0611510A (ja) * | 1992-03-05 | 1994-01-21 | Boehringer Mannheim Gmbh | ヘモグロビン誘導体の測定のための免疫学的方法 |
US5294336A (en) | 1989-09-18 | 1994-03-15 | Hitachi, Ltd. | Apparatus for liquid chromatography for separating AIC components from hemoglobin in blood |
JPH07120447A (ja) | 1993-10-25 | 1995-05-12 | Hitachi Ltd | グリコヘモグロビン分析計 |
JPH07270387A (ja) * | 1994-03-28 | 1995-10-20 | Hitachi Ltd | マルチチャンネルクロマトグラム解析方法及び装置 |
JPH08159954A (ja) * | 1994-12-07 | 1996-06-21 | Tosoh Corp | グリコヘモグロビン測定用の吸光度計 |
US5692503A (en) | 1995-03-10 | 1997-12-02 | Kuenstner; J. Todd | Method for noninvasive (in-vivo) total hemoglobin, oxyhemogolobin, deoxyhemoglobin, carboxyhemoglobin and methemoglobin concentration determination |
JP2002369814A (ja) * | 2001-04-19 | 2002-12-24 | Samsung Electronics Co Ltd | 非侵襲的なヘモグロビン濃度及び酸素飽和度のモニタリング方法並びに装置 |
WO2004057285A1 (en) * | 2002-12-19 | 2004-07-08 | Koninklijke Philips Electronics N.V. | Optical analysis system |
JP2004526141A (ja) * | 2001-02-07 | 2004-08-26 | ユニヴァーシティ カレッジ ロンドン | 組織から得た広帯域弾性散乱スペクトルを処理する方法 |
JP2004309250A (ja) * | 2003-04-04 | 2004-11-04 | Shimadzu Corp | クロマトグラフ用データ処理装置 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4407961A (en) * | 1981-03-16 | 1983-10-04 | Sanders James L | Ion-exchange system and method for isolation and determination of glycosylated hemoglobin in human blood |
US4465774A (en) * | 1981-07-16 | 1984-08-14 | Sherwood Medical Company | Standard or control material for glysocylated or total hemoglobin determination |
US4807148A (en) * | 1987-05-29 | 1989-02-21 | Hewlett-Packard Company | Deconvolving chromatographic peaks |
JPH05113441A (ja) * | 1991-04-18 | 1993-05-07 | Tosoh Corp | 糖化ヘモグロビンの分析法 |
US5543315A (en) * | 1992-06-30 | 1996-08-06 | Kyoto Daiichi Kagaku Co., Ltd. | Method for stabilizing measurement values by high speed liquid chromatography |
JP3262631B2 (ja) * | 1993-04-27 | 2002-03-04 | 積水化学工業株式会社 | 糖化ヘモグロビン測定用標準物質およびその製造法 |
DE69430152T2 (de) | 1993-06-25 | 2002-10-31 | Edward W. Stark | Verfahren und Vorrichtung zum Messen von Glukoseverwandten Substanzen |
US5644503A (en) | 1994-03-28 | 1997-07-01 | Hitachi, Ltd. | Methods and apparatuses for analyzing multichannel chromatogram |
JPH08233824A (ja) * | 1994-12-19 | 1996-09-13 | Bio Rad Lab Inc | カラム再生をしないクロマトグラフィによる糖化ヘモグロビンの連続測定法 |
JPH11142326A (ja) * | 1997-11-07 | 1999-05-28 | Kdk Corp | グリコヘモグロビン測定用の吸光度計 |
-
2007
- 2007-03-23 CN CN2007800187887A patent/CN101484792B/zh active Active
- 2007-03-23 JP JP2008507482A patent/JP5279485B2/ja active Active
- 2007-03-23 EP EP07739551.5A patent/EP2012111B1/en active Active
- 2007-03-23 US US12/225,540 patent/US8268625B2/en active Active
- 2007-03-23 WO PCT/JP2007/056110 patent/WO2007111282A1/ja active Application Filing
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5294336A (en) | 1989-09-18 | 1994-03-15 | Hitachi, Ltd. | Apparatus for liquid chromatography for separating AIC components from hemoglobin in blood |
JPH0611510A (ja) * | 1992-03-05 | 1994-01-21 | Boehringer Mannheim Gmbh | ヘモグロビン誘導体の測定のための免疫学的方法 |
JPH05256851A (ja) * | 1992-03-16 | 1993-10-08 | Hitachi Ltd | 糖化ヘモグロビンの測定方法及び装置 |
JPH07120447A (ja) | 1993-10-25 | 1995-05-12 | Hitachi Ltd | グリコヘモグロビン分析計 |
JPH07270387A (ja) * | 1994-03-28 | 1995-10-20 | Hitachi Ltd | マルチチャンネルクロマトグラム解析方法及び装置 |
JPH08159954A (ja) * | 1994-12-07 | 1996-06-21 | Tosoh Corp | グリコヘモグロビン測定用の吸光度計 |
US5692503A (en) | 1995-03-10 | 1997-12-02 | Kuenstner; J. Todd | Method for noninvasive (in-vivo) total hemoglobin, oxyhemogolobin, deoxyhemoglobin, carboxyhemoglobin and methemoglobin concentration determination |
JP2004526141A (ja) * | 2001-02-07 | 2004-08-26 | ユニヴァーシティ カレッジ ロンドン | 組織から得た広帯域弾性散乱スペクトルを処理する方法 |
JP2002369814A (ja) * | 2001-04-19 | 2002-12-24 | Samsung Electronics Co Ltd | 非侵襲的なヘモグロビン濃度及び酸素飽和度のモニタリング方法並びに装置 |
WO2004057285A1 (en) * | 2002-12-19 | 2004-07-08 | Koninklijke Philips Electronics N.V. | Optical analysis system |
JP2004309250A (ja) * | 2003-04-04 | 2004-11-04 | Shimadzu Corp | クロマトグラフ用データ処理装置 |
Non-Patent Citations (1)
Title |
---|
See also references of EP2012111A4 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012500401A (ja) * | 2008-08-21 | 2012-01-05 | バイオ−ラッド ラボラトリーズ,インコーポレイティド | 分析物の比を決定する校正表面方法 |
JP2010181350A (ja) * | 2009-02-09 | 2010-08-19 | Shimadzu Corp | クロマトグラフ用データ処理装置 |
JP2013529780A (ja) * | 2010-06-25 | 2013-07-22 | インペリアル イノベイションズ リミテッド | 小型hplc装置 |
US9354209B2 (en) | 2010-06-25 | 2016-05-31 | Imperial Innovations Ltd | Miniature HPLC device |
JPWO2016147415A1 (ja) * | 2015-03-19 | 2017-10-19 | 株式会社島津製作所 | クロマトグラフ用制御装置 |
US10712320B2 (en) | 2015-10-14 | 2020-07-14 | Alps Alpine Co., Ltd. | Flow channel structure and measuring device for measurement target liquid |
JP2019007865A (ja) * | 2017-06-26 | 2019-01-17 | アークレイ株式会社 | 液体クロマトグラフィ装置 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2007111282A1 (ja) | 2009-08-13 |
JP5279485B2 (ja) | 2013-09-04 |
US20100291691A1 (en) | 2010-11-18 |
CN101484792B (zh) | 2011-05-18 |
EP2012111A1 (en) | 2009-01-07 |
EP2012111B1 (en) | 2014-07-16 |
CN101484792A (zh) | 2009-07-15 |
EP2012111A4 (en) | 2009-07-15 |
US8268625B2 (en) | 2012-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007111282A1 (ja) | グリコヘモグロビン濃度測定方法および濃度測定装置 | |
JP5710739B2 (ja) | 血液分析装置 | |
EP1869431B1 (en) | Device for determining of properties in a fluid and/or constituents thereof | |
AU2012241983B2 (en) | Method and apparatus for monitoring a treatment of a patient, preferably for monitoring hemodialysis, hemodiafiltration, and/or peritoneal dialysis | |
JP4989628B2 (ja) | グリコヘモグロビン濃度測定方法および濃度測定装置 | |
JP5324913B2 (ja) | 脱気装置およびそれを備えた液体クロマトグラフィ装置 | |
JP2013195139A (ja) | 分析装置、分析プログラム及び分析方法 | |
JP5260967B2 (ja) | 液体クロマトグラフィ装置 | |
JP2007212277A (ja) | 液体クロマトグラフィ装置 | |
WO2022208445A2 (en) | Multiparametric optical method and device for determining uremic solutes, including uremix toxins, in biological fluids | |
US20140095082A1 (en) | Expanded linear range by use of two flow cell detectors with long and short path | |
JP6435165B2 (ja) | 液体クロマトグラフィ測定方法、液体クロマトグラフィ測定装置、及び液体クロマトグラフィ測定プログラム | |
JP6895819B2 (ja) | 液体クロマトグラフィ装置 | |
JP2007240500A (ja) | 液体クロマトグラフィ装置 | |
CN117110508A (zh) | 稳定型糖化血红蛋白的测定方法、测定装置和非暂时性计算机可读存储介质 | |
JPH06288923A (ja) | 水中のシリカ成分の分析装置 | |
JP2007240499A (ja) | 試料調製方法および液体クロマトグラフィ装置 | |
JPS62102141A (ja) | 化学反応の微量分析方法および装置 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780018788.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07739551 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008507482 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007739551 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12225540 Country of ref document: US |